The study of Chen et al. (25) found that the gradient boosting classifier models based on MRI radiomics and clinical factors had a tremendous predictive effect on the survival of brain metastatic NSCLC patients with EGFR, ALK, and/or KRAS mutation (AUC: 0.977, 0.905, and 0.947, respectively). This evidence concerns the gene KRAS and non-small cell lung carcinoma.